Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902. Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary - Primary - Neuro-Onc - N0874 , ABTC-0902
Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology Cerhan, Jane H , Anderson, S Keith , Butts, Alissa M , Porter, Alyx B ... - - Neurooncol Pract - 2019 Manuscript - Secondary-not-in-original - Primary - Health Outcome - N0577 , A221101 , N0874 , N107C
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma Ellingson, Benjamin M , Abrey, Lauren E , Nelson, Sarah J ... - - Neuro-oncology - 2018 Manuscript - Secondary-not-in-original - Primary - Neuro-Onc - N0874
Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial Galanis, E. , Sarkaria, J. , Anderson, K. , Wu, W. , Jaeckle, K. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary - Primary - Neuro-Onc - N0874
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02 Galanis, Evanthia , Anderson, S Keith , Miller, C Ryan ... - - Neuro-oncology - 2018 Manuscript - Primary - Primary - Neuro-Onc - N0874
Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902) Galanis, Evanthia , Anderson, S. Keith , Miller, C. Ryan ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - Neuro-Onc - N0874